Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
QuintilesIMS
Merck
Julphar
Argus Health
Chubb
Cantor Fitzgerald
Fuji
Healthtrust

Generated: October 22, 2017

DrugPatentWatch Database Preview

LAMICTAL XR Drug Profile

« Back to Dashboard

Which patents cover Lamictal Xr, and what generic Lamictal Xr alternatives are available?

Lamictal Xr is a drug marketed by Glaxosmithkline Llc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-three patent family members in thirty-eight countries.

The generic ingredient in LAMICTAL XR is lamotrigine. There are thirty-two drug master file entries for this compound. Sixty-seven suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.

Summary for Tradename: LAMICTAL XR

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list75
Clinical Trials: see list55
Patent Applications: see list4,585
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:LAMICTAL XR at DailyMed

Pharmacology for Tradename: LAMICTAL XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-001May 29, 2009ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-004May 29, 2009ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-002May 29, 2009ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-005Apr 14, 2010ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-004May 29, 2009ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-001May 29, 2009ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-002May 29, 2009ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-003May 29, 2009ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-003May 29, 2009ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-006Jun 21, 2011ABRXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for LAMICTAL XR

Drugname Dosage Strength RLD Submissiondate
lamotrigineExtended-release Tablets25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mgLamictal XR2/12/2014

International Patent Family for Tradename: LAMICTAL XR

Country Document Number Estimated Expiration
MexicoPA05001243► Subscribe
South Korea100882707► Subscribe
African Intellectual Property Organization (OAPI)12770► Subscribe
Colombia5680405► Subscribe
Argentina038417► Subscribe
South Korea101048925► Subscribe
United Kingdom0203298► Subscribe
European Patent Office1474114► Subscribe
Poland213565► Subscribe
Ukraine81756► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Boehringer Ingelheim
AstraZeneca
McKinsey
Healthtrust
Johnson and Johnson
Farmers Insurance
US Department of Justice
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot